BOLD vs INCY · P/E 0.1, $24.6M cap vs P/E 14, rev $5.14B
Boundless Bio, Inc. Common Stock (BOLD) versus Incyte Corporation (INCY) — a side-by-side from cached financials, not a winner call.
Boundless Bio, Inc. Common Stock (BOLD) is a biotechnology company listed on US.
Incyte Corporation (INCY) is a biotechnology company listed on US.
BOLD does not have a complete income-statement cache yet.
Latest reported INCY revenue for 2025-12-31 was $5.14B. Net income was $1.29B. Revenue was up 21.2% from 2024-12-31 to 2025-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
BOLD currently screens at market cap $24.6M and trailing P/E 0.1. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
Not investment advice. Open the BOLD and INCY stock pages for the full models.
Not investment advice.